GeoVax Labs, Inc.
GOVXHealthcareNASDAQBiotechnology · Last scanned Jul 22, 2026
Scan Results
Daily timeframeGeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the. The $5.2M market capitalization puts GOVX squarely in micro-cap range for its industry. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine.
Market Cap
$5.2M
Beta
3.67
P/E (TTM)
—
P/E (Fwd)
-1.16
EPS (TTM)
$-13.85
EPS (Fwd)
$-0.86
ROE
-509.3%
ROA
-194.6%
Cash
$1.3M
Total Debt
$394,571
Free CF
-$11.2M
52W Change
-95.2%
Annual Financials
Cash vs Debt
Where GOVX stands vs its 150-day and 200-day moving averages
As of the July 7, 2026 close, GOVX finished 55.83% below its 150-day moving average ($2.83) and 77.40% below its 200-day moving average ($5.53). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is GOVX overbought or oversold?
At the July 7, 2026 close, GOVX's RSI(14) was 52.4, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $1.3M in cash comfortably exceeding the $395K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$11.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -509.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $82K to $2.5M.
With a beta above 1.5, GOVX tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. With cash comfortably exceeding debt, GOVX has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence GeoVax Labs, Inc.'s trajectory.